How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,855 results for

Imiquimod

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Anti-hepatitis B virus (HBV) response of imiquimod based toll like receptor 7 ligand in hbv-positive human hepatocelluar carcinoma cell line. Full Text available with Trip Pro

Anti-hepatitis B virus (HBV) response of imiquimod based toll like receptor 7 ligand in hbv-positive human hepatocelluar carcinoma cell line. Toll like receptors (TLRs) play an important role in innate immunity and various studies suggest that TLRs play a crucial role in pathogenesis of hepatitis B virus (HBV) infection. The present study aims in looking into the status of crucial host and viral gene expression on inciting TLR7.The transcription of TLR7 pathway signaling molecules and HBV DNA (...) viral load were quantified by Real Time-PCR after stimulation of TLR7 with its imiquimod based ligand, R837. Cell cycle analysis was performed using flow-cytometry. Expression of TLR7 and chief cell cycle regulator governing G1/S transition, p53 was also seen in liver biopsysss samples of CHB patients. HBV induced alteration in histone modifications in HepG2 cells and its restoration on TLR7 activation was determined using western blot.The TLR7 expression remains downregulated in HepG2.2.15 cells

2017 BMC Infectious Diseases

122. Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series. (Abstract)

Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series. To demonstrate the clinical efficacy of topical 5% imiquimod for mycosis fungoides (MF) tumors.Treatment of tumor-stage MF represents a therapeutic challenge because of a limited number of effective topical therapies. Single tumors can be treated with localized radiation but may recur. Systemic therapies are also an option but are associated with serious adverse effects. Imiquimod is a topical agent whose (...) efficacy has been documented in treating MF patches and plaques as well as one case of tumor-stage disease.We present two stage IIB MF patients, including one with large cell transformation, whose tumors were treated with imiquimod 5% cream after failing prior therapies.The MF tumors in both patients demonstrated a complete response to imiquimod 5% cream without recurrence over 8 years and 2 years of follow-up, respectively. One patient experienced application site irritation and flu-like symptoms

2017 Journal of Dermatological Treatment

123. Imiquimod-applied Interleukin-10 deficient mice better reflects severe and persistent psoriasis with systemic inflammatory state. (Abstract)

Imiquimod-applied Interleukin-10 deficient mice better reflects severe and persistent psoriasis with systemic inflammatory state. Previous studies have shown that imiquimod-induced psoriasis-like skin inflammation in mice resembles phenotypic changes and cytokine profiles of human psoriasis. However, a psoriasis animal model reflecting the chronic inflammatory course and comorbidities has not yet been established. We aimed to evaluate the imiquimod-applied interleukin (IL)-10 deficient mouse (...) model in comparison with previous models. IL-10 deficient and wild-type (WT) mice received either imiquimod or vehicle cream for 12 days and were sacrificed on day 15. For earlier time point data, either imiquimod or vehicle cream was applied for 2 days, and the mice were sacrificed on day 3. Imiquimod-applied IL-10 deficient mice showed more persistent psoriasis-like inflammation and higher severity index than did WT between day 8 and 15. Histopathologically, they demonstrated significantly thicker

2017 Experimental Dermatology

124. Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection. Full Text available with Trip Pro

Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection. Transcutaneous immunization (TCI) is a novel vaccination strategy utilizing the skin associated lymphatic tissue to induce immune responses. TCI using a cytotoxic T lymphocyte (CTL) epitope and the Toll-like receptor 7 (TLR7) agonist imiquimod mounts strong CTL responses by activation and maturation of skin-derived dendritic cells (DCs) and their migration to lymph nodes (...) . However, TCI based on the commercial formulation Aldara only induces transient CTL responses that needs further improvement for the induction of durable therapeutic immune responses.Therefore we aimed to develop a novel imiquimod solid nanoemulsion (IMI-Sol) for TCI with superior vaccination properties suited to induce high quality T cell responses for enhanced protection against infections.TCI was performed by applying a MHC class I or II restricted epitope along with IMI-Sol or Aldara (each

2017 Journal of dermatological science

125. Imiquimod treatment for lentigo maligna - LIMIT-1 trial. (Abstract)

Imiquimod treatment for lentigo maligna - LIMIT-1 trial. 28369728 2017 11 07 2018 12 02 1365-2133 177 1 2017 07 The British journal of dermatology Br. J. Dermatol. Imiquimod treatment for lentigo maligna: LIMIT-1 trial. 324-325 10.1111/bjd.15511 Maher N G NG Melanoma Institute Australia, Sydney, Australia. The University of Sydney, Sydney, Australia. Guitera P P Melanoma Institute Australia, Sydney, Australia. The University of Sydney, Sydney, Australia. Sydney Melanoma Diagnostic Centre, Royal (...) Prince Alfred Hospital, Sydney, Australia. eng Letter Comment 2017 05 23 England Br J Dermatol 0004041 0007-0963 0 Aminoquinolines 0 Antineoplastic Agents P1QW714R7M Imiquimod IM Br J Dermatol. 2017 May;176(5):1148-1154 27714781 Aminoquinolines Antineoplastic Agents Humans Hutchinson's Melanotic Freckle Imiquimod Lentigo Skin Neoplasms 2017 4 4 6 0 2017 11 8 6 0 2017 4 4 6 0 ppublish 28369728 10.1111/bjd.15511

2017 British Journal of Dermatology

126. Imiquimod-induced autophagy is regulated by ER stress-mediated PKR activation in cancer cells. Full Text available with Trip Pro

Imiquimod-induced autophagy is regulated by ER stress-mediated PKR activation in cancer cells. Autophagy is a highly conserved cellular catabolic pathway for degradation and recycling of intracellular components in response to nutrient starvation or environmental stress. Endoplasmic reticulum (ER) homeostasis can be disturbed by physiological and pathological influences, resulting in accumulation of misfolded and unfolded proteins in the ER lumen, a condition referred to as ER stress. Imiquimod

2017 Journal of dermatological science

127. Imiquimod induced ApoE-deficient mice might be a composite animal model for the study of psoriasis and dyslipideamia comorbidity. Full Text available with Trip Pro

Imiquimod induced ApoE-deficient mice might be a composite animal model for the study of psoriasis and dyslipideamia comorbidity. Psoriasis patients are at increased risk of developing lipid metabolism disturbances. Both psoriasis and dyslipideamia not only closely interact in disease development, but occur as mutual side effects in some medicine treatment. The interactive mechanism of the two diseases is complicated and still unclear.Here, we proposed applying imiquimod on the dorsal skin (...) of ApoE-/- mice to establish a composite animal model which formed psoriasiform skin lesions under hyperlipidemic condition.By comparison with corresponding wild-type(C57BL/6) mice, the composite mice model was evaluated by skin pathological features, lipid levels, immune inflammatory factors in order to clarify the diseases interplay mechanism. In addition, IL-17 mAb treatment was applied to observe the effect of IL-17 antibody on the composite animal model.The results verified that imiquimod-induced

2017 Journal of dermatological science

128. Human Papillomavirus DNA methylation predicts response to treatment using cidofovir and imiquimod in Vulval Intraepithelial Neoplasia 3. Full Text available with Trip Pro

Human Papillomavirus DNA methylation predicts response to treatment using cidofovir and imiquimod in Vulval Intraepithelial Neoplasia 3. Purpose: Response rates to treatment of vulval intraepithelial neoplasia (VIN) with imiquimod and cidofovir are approximately 57% and 61%, respectively. Treatment is associated with significant side effects and, if ineffective, risk of malignant progression. Treatment response is not predicted by clinical factors. Identification of a biomarker that could (...) with response to treatment. For cidofovir (n = 30), median E2 methylation was significantly higher in patients who responded (P ≤ 0.0001); E2 methylation >4% predicted response with 88.2% sensitivity and 84.6% specificity. For imiquimod (n = 33), median E2 methylation was lower in patients who responded to treatment (P = 0.03; not significant after Bonferroni correction); E2 methylation <4% predicted response with 70.6% sensitivity and 62.5% specificity.Conclusions: These data indicate that cidofovir

2017 Clinical Cancer Research

129. Blocking mTOR Signalling with Rapamycin Ameliorates Imiquimod-induced Psoriasis in Mice. Full Text available with Trip Pro

Blocking mTOR Signalling with Rapamycin Ameliorates Imiquimod-induced Psoriasis in Mice. The mTOR (mechanistic target of rapamycin) inhibitor rapamycin has long been known for its immune suppressive properties, but it has shown limited therapeutic success when given systemically to patients with psoriasis. Recent data have shown that the mTOR pathway is hyperactivated in lesional psoriatic skin, which probably contributes to the disease by interfering with maturation of keratinocytes (...) . This study investigated the effect of topical rapamycin treatment in an imiquimod-induced psoriatic mouse model. The disease was less severe if the mice had received rapamycin treatment. Immunohistological analysis revealed that rapamycin not only prevented the activation of mTOR signalling (P-mTOR and P-S6 levels), but almost normalized the expression of epidermal differentiation markers. In addition, the influx of innate immune cells into the draining lymph nodes was partially reduced by rapamycin

2017 Acta Dermato-Venereologica

130. A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. (Abstract)

A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. Imiquimod is a toll-like receptor agonist with proven antitumor activity as a topical treatment for skin cancer. TMX-101 (Vesimune) is a novel liquid formulation of imiquimod optimized for intravesical delivery. The agent demonstrated safety as an intravesical treatment for non-muscle-invasive bladder cancer in a phase 1 clinical trial. We report the results of a phase 2 prospective

2017 Urologic oncology

131. Long-Term Outcomes of Melanoma In Situ Treated With Topical 5% Imiquimod Cream: A Retrospective Review. (Abstract)

Long-Term Outcomes of Melanoma In Situ Treated With Topical 5% Imiquimod Cream: A Retrospective Review. Melanoma in situ (MIS) is a noninvasive form of melanoma for which nonsurgical therapeutic options continue to be explored. The off-label use of topical 5% imiquimod cream in the management of MIS has shown potential but reported recurrence rates vary considerably between 0% and 40%. Furthermore, the long-term efficacy of imiquimod is not well established.To determine the recurrence rate (...) of MIS among patients treated with topical 5% imiquimod cream at Dartmouth-Hitchcock Medical Center with at least 1 year of follow-up.A retrospective chart review identified 12 patients with MIS who have been treated with topical 5% imiquimod cream for 6 to 12 weeks. Patients who underwent surgical treatment for MIS were excluded from analysis.Of 12 patients with histologically confirmed MIS treated with topical 5% imiquimod cream, there were 2 recurrences (17%) during a median follow-up time of 5.5

2017 Dermatologic Surgery

132. Involvement of µ-opioid Receptors and κ-opioid Receptors in Itch-related Scratching Behaviour of Imiquimod-induced Psoriasis-like Dermatitis in Mice. Full Text available with Trip Pro

Involvement of µ-opioid Receptors and κ-opioid Receptors in Itch-related Scratching Behaviour of Imiquimod-induced Psoriasis-like Dermatitis in Mice. The pathogenesis of psoriatic itch is poorly understood. The aim of this study was to investigate the involvement of opioid receptors in scratching behaviour of imiquimod-induced psoriasis-like dermatitis model mice. Topical application of 5% imiquimod cream to the rostral back skin of mice induced antihistamine-resistant scratching behaviour (...) . The expression of µ-opioid receptor (MOR) protein increased in the epidermis, dorsal root ganglia (DRG) and spinal cord of imiquimod-treated mice. In contrast, the expression of κ-opioid receptor (KOR) protein decreased in the DRG and spinal cord of imiquimod-treated mice, and was undetectable in the epidermis of both groups. Topical or intraperitoneal administration of the MOR antagonist naloxone and oral administration of the centrally acting KOR agonist ICI-199,441 inhibited scratching behaviour, whereas

2017 Acta Dermato-Venereologica

133. Imiquimod

Imiquimod Imiquimod Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Imiquimod Imiquimod Aka: Imiquimod , Aldara From Related Chapters (...) warts Apply 3 times per week for a maximum of 16 weeks Apparently very effective if extensive involvement Molloscum contagiosum Apply to skin lesion for 6-10 hours, then wash off Apply 3 times weekly for 4 to 16 weeks VI. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Imiquimod." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Cost

2018 FP Notebook

134. The Immunomodulatory Small Molecule Imiquimod Induces Apoptosis in Devil Facial Tumour Cell Lines. Full Text available with Trip Pro

The Immunomodulatory Small Molecule Imiquimod Induces Apoptosis in Devil Facial Tumour Cell Lines. The survival of the Tasmanian devil (Sarcophilus harrisii) is threatened by devil facial tumour disease (DFTD). This transmissible cancer is usually fatal, and no successful treatments have been developed. In human studies, the small immunomodulatory molecule imiquimod is a successful immunotherapy, activating anti-tumour immunity via stimulation of toll-like receptor-7 (TLR7) signaling pathways (...) . In addition, imiquimod is a potent inducer of apoptosis in human tumour cell lines via TLR7 independent mechanisms. Here we investigate the potential of imiquimod as a DFTD therapy through analysis of treated DFTD cell lines and Tasmanian devil fibroblasts. WST-8 proliferation assays and annexin V apoptosis assays were performed to monitor apoptosis, and changes to the expression of pro- and anti-apoptotic genes were analysed using qRT-PCR. Our results show that DFTD cell lines, but not Tasmanian devil

2016 PLoS ONE

135. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RTVIN): a multicentre, open-label, randomised, phase 2 trial Full Text available with Trip Pro

Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RTVIN): a multicentre, open-label, randomised, phase 2 trial Vulval intraepithelial neoplasia is a skin disorder affecting the vulva that, if left untreated, can become cancerous. Currently, the standard treatment for patients with vulval intraepithelial neoplasia is surgery, but this approach does not guarantee cure and can be disfiguring, causing physical and psychological problems (...) , particularly in women of reproductive age. We aimed to assess the activity, safety, and feasibility of two topical treatments--cidofovir and imiquimod--as an alternative to surgery in female patients with vulval intraepithelial neoplasia.We recruited female patients (age 16 years or older) from 32 centres to an open-label, randomised, phase 2 trial. Eligibility criteria were biopsy-proven vulval intraepithelial neoplasia grade 3 and at least one lesion that could be measured accurately. We randomly

2014 EvidenceUpdates Controlled trial quality: predicted high

136. The Snowballing Literature on Imiquimod-Induced Skin Inflammation in Mice: A Critical Appraisal. Full Text available with Trip Pro

The Snowballing Literature on Imiquimod-Induced Skin Inflammation in Mice: A Critical Appraisal. Since 2009, the imiquimod- or Aldara-induced (3M Pharmaceuticals, St. Paul, MN) model of acute skin inflammation has become the most widely used mouse model in preclinical psoriasis studies. Although this model offers researchers numerous benefits, there are important limitations and possible confounding variables to consider. The imiquimod model requires careful consideration and warrants scrutiny

2016 Journal of Investigative Dermatology

137. Activation of Langerhans cells promotes the inflammation in imiquimod-induced psoriasis-like dermatitis. (Abstract)

Activation of Langerhans cells promotes the inflammation in imiquimod-induced psoriasis-like dermatitis. Langerhans cells (LCs) are epidermis-resident dendritic cells that sense and mediate stimuli from skin and outside world, and participate in various skin diseases, playing either pro-inflammatory or regulatory roles. However, the exact function of LCs in the pathogenesis of psoriasis remains unclear, and the conclusions of previous studies are controversial.To explore the role of LCs (...) in mouse model of imiquimod (IMQ)-induced psoriasis-like dermatitis using langerin-diphtheria toxin A (DTA) mice that are constitutively deficient in LCs.IMQ (Aldara) was painted on the skin of mice to produce psoriasis-like dermatitis, and inflammation was evaluated by gross ear thickness, histopathology, flow cytometry and cytokine production. Bone marrow transplantation and fluorescein isothiocyanate tracing were applied to access the migration of LCs.The severity of IMQ-induced dermatitis

2016 Journal of dermatological science

138. TRIM21 is important in the early phase of inflammation in the imiquimod-induced psoriasis-like skin inflammation mouse model. (Abstract)

TRIM21 is important in the early phase of inflammation in the imiquimod-induced psoriasis-like skin inflammation mouse model. Tripartite motif-containing protein 21 (TRIM21) regulates pro-inflammatory cytokines and type I interferons and acts as an autoantigen in certain autoimmune diseases, but TRIM21 has not been investigated in psoriasis. It has been suggested that TRIM21 may have a dual function; in the early phase of inflammation, it may function as a stimulator; but upon immune (...) stimulation, its ubiquitinating mode of action may shift from stabilization to degradation of IRF3 causing inhibition of the immune responses. The imiquimod (IMQ)-induced psoriasis-like mouse model displays features similar to those of human psoriasis. However, chronicity is lacking in this model. We investigated whether the role of TRIM21 in psoriasis was pro-inflammatory or anti-inflammatory. We hypothesized that a shift of the TRIM21-ubiquitinating mode of action may explain the lack of chronicity

2016 Experimental Dermatology

139. Polyinosinic-polycytidylic acid (poly(I:C)) attenuates imiquimod-induced skin inflammation in mice by increasing cutaneous PD-L1 expression. Full Text available with Trip Pro

Polyinosinic-polycytidylic acid (poly(I:C)) attenuates imiquimod-induced skin inflammation in mice by increasing cutaneous PD-L1 expression. 27897321 2018 09 18 2018 12 02 1600-0625 26 4 2017 04 Experimental dermatology Exp. Dermatol. Polyinosinic-polycytidylic acid (poly(I:C)) attenuates imiquimod-induced skin inflammation in mice by increasing cutaneous PD-L1 expression. 346-348 10.1111/exd.13266 Cho Kyung-Ah KA 0000-0003-3758-4209 Department of Microbiology, School of Medicine, Ewha Womans (...) Dermatol 9301549 0906-6705 0 Aminoquinolines 0 B7-H1 Antigen 0 CD274 protein, human 0 Cd274 protein, mouse 0 TLR3 protein, human 0 Toll-Like Receptor 3 O84C90HH2L Poly I-C P1QW714R7M Imiquimod IM Aminoquinolines Animals B7-H1 Antigen metabolism Cell Line, Transformed Dermatitis immunology metabolism Disease Models, Animal Humans Imiquimod Keratinocytes immunology metabolism Mice Poly I-C Psoriasis immunology metabolism Toll-Like Receptor 3 metabolism PD-L1 keratinocyte poly(I:C) psoriasis 2016 10 24

2016 Experimental Dermatology

140. Effect of topical imiquimod as primary treatment for lentigo maligna - the LIMIT-1 study. Full Text available with Trip Pro

Effect of topical imiquimod as primary treatment for lentigo maligna - the LIMIT-1 study. Topical imiquimod is sometimes used for lentigo maligna (LM) in situ melanoma instead of surgery, but frequency of cure is uncertain. Pathological complete regression (pCR) is a logical surrogate marker for cure after imiquimod, although residual LM and atypical melanocytic hyperplasia may not be reliably distinguished. A trial comparing imiquimod vs. surgery might be justified by a high imiquimod pCR (...) rate.Primary: to estimate the pCR rate for LM following imiquimod. Secondary: to assess the accuracy of prediction of pCR, using clinical complete regression (cCR) plus negative post-treatment biopsies, tolerability, resource use, patients' preferences and induced melanoma immunity.This was a single-arm phase II trial of 60 imiquimod applications over 12 weeks for LM then radical resection. A pCR rate ≥ 25 out of 33 would reliably discriminate between pCR rates < 60% and ≥ 85%. Clinical response

2016 British Journal of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>